Home » FDA Issues Advice on Replacement or Corrective Therapies for Certain Rare Diseases
FDA Issues Advice on Replacement or Corrective Therapies for Certain Rare Diseases
The FDA published a draft guidance recommending ways to demonstrate if new drugs or drug uses are effective for certain low-prevalence rare diseases caused by single enzyme defects.
The guidance applies to diseases that have well-characterized pathophysiology and whose changes in substrate deposition can be effectively measured in the affected tissues; it does not apply to rare diseases that progress rapidly.
“There are many reasons that make demonstration of effectiveness extremely challenging for drugs intended to treat slowly progressive, low-prevalence rare diseases that result from defects in a single enzyme,” the agency said.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May